This experiment elucidates the neuroprotective mechanism of GLP-1 (Glucagon-Like Peptide-1) agonists in Parkinson's disease models, determining the critical downstream pathways and cellular targets.
Primary Hypothesis: GLP-1 agonist neuroprotection in PD is mediated through activation of GLP-1R on microglia, leading to reduced neuroinflammation and enhanced mitochondrial function in dopaminergic neurons.
Secondary Hypothesis: Combined GLP-1R and GIPR activation will show synergistic neuroprotection.
GLP-1 agonists are approved for type 2 diabetes and have shown promise in neurodegenerative diseases. Several clinical trials are underway for Parkinson's disease (e.g., liraglutide, exenatide). However, the mechanism of neuroprotection remains unclear.
Key questions:
- What is the cellular target of GLP-1 agonist neuroprotection?
- Which downstream signaling pathways are critical?
- Is peripheral vs. central GLP-1R activation required?
- Primary: MPTP-treated C57BL/6J mice (classic PD model)
- Secondary: α-synuclein preformed fibril (PFF) model
- GLP-1R knockout mice for genetic validation
- Vehicle control (saline)
- Liraglutide (25 nmol/kg, daily IP)
- Exenatide (25 nmol/kg, daily IP)
- GLP-1R knockout + liraglutide
- GIPR agonist (25 nmol/kg) + liraglutide (combination)
- Anti-inflammatory control (minocycline)
- Mitochondrial protector control (coenzyme Q10)
- Pre-treatment: 2 weeks
- MPTP/PFF administration: 2 weeks
- Continued treatment: 4 weeks post-lesion
- Behavioral testing: weeks 6-8
- Terminal endpoint: week 8
- Primary:
- Dopaminergic neuron survival (TH immunohistochemistry in substantia nigra)
- Striatal dopamine levels (HPLC)
- Secondary:
- Motor behavior (cylinder test, gait analysis, rotarod)
- Neuroinflammation (Iba1, CD68, GFAP, cytokine levels)
- Mitochondrial function ( Seahorse assay, complex I activity)
- GLP-1R expression (qPCR, Western blot)
- cAMP/PKA signaling pathway activation
- ERK and Akt phosphorylation
¶ Reagents and Equipment
| Item |
Supplier |
Cost (USD) |
| Liraglutide |
Sigma |
$2,500 |
| Exenatide |
Sigma |
$2,000 |
| GIPR agonist |
Bachem |
$3,000 |
| MPTP |
Sigma |
$1,500 |
| α-synuclein PFF |
rPeptide |
$5,000 |
| TH antibody |
Pel-Freez |
$800 |
| Iba1 antibody |
Wako |
$350 |
| Cytokine array |
R&D Systems |
$4,000 |
| Seahorse XF analyzer |
Agilent |
$300/hour |
| HPLC system |
Shimadzu |
$200/sample |
| Gait analysis system |
CleverSys |
$25,000 |
Estimated Total Cost: $110,000
- Imperial College London — Dr. Marcel van der Laan's group (GLP-1 in CNS)
- University of Oxford — Dr. Frances的白's group (mitochondrial function)
- Johns Hopkins — Dr. Ted Dawson's group (PD models)
- Arizona State University — Dr. Patrick Davis's group (neuroinflammation)
- Months 1-2: Colony establishment, reagent ordering
- Months 3-5: Treatment and behavioral testing
- Months 6-7: Tissue processing and biochemistry
- Months 8-9: Data analysis
- Month 10: Manuscript preparation
Total Duration: 10 months
- 40-60% protection of TH+ neurons with liraglutide
- Restoration of striatal dopamine to 70-80% of control levels
- Dose-response relationship established
- Significant improvement in cylinder test and rotarod
- 50% reduction in activated microglia
- Restored mitochondrial respiration (complex I activity)
- cAMP/PKA pathway activation confirmed
- Synergy with GIPR agonist (additional 20% benefit)
- Careful MPTP handling with safety protocols
- Regular animal health monitoring
- Pre-specified statistical analysis plan
- Littermate controls for knockout studies
| Dimension |
Score (1-10) |
Rationale |
| Scientific Value |
9 |
Elucidates mechanism of promising therapeutic class |
| Feasibility |
8 |
Standard PD models and GLP-1 agonists available |
| Novelty |
8 |
First comprehensive mechanistic study |
| Disease Impact |
9 |
Could improve GLP-1 agonist clinical trials |
| Reach |
8 |
Relevant to both PD and diabetes-related neurodegeneration |
| Cost Efficiency |
7 |
Moderate cost for mechanistic depth |
| Time Efficiency |
8 |
10-month timeline reasonable |
| Evidence Base |
9 |
Strong clinical trial data supporting approach |
| Addresses Uncertainty |
10 |
Resolves critical mechanism questions |
| Translation Potential |
9 |
Direct relevance to clinical development |
Total Score: 85 × weight normalization = 85/120